查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464691

病毒載體和質粒 DNA 製造市場，按載體類型、工作流程、應用、最終用途、治療領域、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Viral Vector and Plasmid DNA Manufacturing Market, By Vector Type, By Workflow, By Application, By End-use, By Therapeutic Area, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 345 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2023年病毒載體和質粒 DNA 製造市場規模為 54.05 億美元，2024年至2032年年複合成長率為 19.7%。

病毒載體與質粒 DNA 製造市場-市場動態

增加政府對細胞研究的支持以推動市場需求

由於政府增加了創建用於生產病毒載體的新技術和設施的資助，增加了整體研究活動並支持了基於細胞的研究，病毒載體和質粒 DNA 製造市場預計將成長。此外，推動市場擴張的主要驅動力是癌症和心臟異常等疾病的日益普及、細胞療法研究的使用以及病毒載體和質粒 DNA 製造領域的技術進步。例如，加拿大政府對基因組學和再生醫學進行投資，以促進公民的健康。透過幹細胞網路的競爭性研究資助計劃，獲得了 430 萬美元。這筆直接資金將支持加拿大各地目的是治療多發性硬化症、肌肉萎縮症、癌症、血液疾病、1 型糖尿病、心臟病和囊性纖維化等健康問題的 16 項措施。本次競賽的資助機會之一是一項新計劃，目的是幫助健康、生物工程和社會科學領域的早期職業研究人員創建幹細胞研究計劃，重點關注再生醫學。此外，加拿大基因組公司也將為十項新的基因組學研究提供 1,600 萬加元。到2035年，這項投資將有助於生物醫學和藥物開發的轉型。它還將支持具有直接應用潛力的任務驅動研究，解決農業、健康和環境領域的現實問題和可能性。

不斷增加的產品發佈為市場收入成長提供了潛在機會

預計不斷增加的產品推出將為預測期內的市場成長提供潛在機會。例如，2023年 3月，透過引進 Charles River Laboratories International, Inc. 的現成 pHelper，現在可以更有效地管理基於腺相關病毒（AAV）的基因治療計劃，從早期發現到商業化生產服務。研究級（RG）、高品質（HQ）和良好生產規範（GMP）等級均可立即獲得。

病毒載體和質粒 DNA 製造市場 - 關鍵見解

根據研究分析師的分析，預計全球市場在預測期內（2024-2032年）每年將以 19.7%左右的年複合成長率成長

基於載體類型細分，腺相關病毒（AAV）細分市場預計將在預測期內佔據最大的市場佔有率

根據工作流程細分，下游製造領域預計將在預測期內佔據重要的市場佔有率

根據治療領域，腫瘤疾病領域預計將在預測期內佔據顯著的市場佔有率

依地區分類，北美是2023年的主要收入來源

病毒載體和質粒 DNA 製造市場區隔分析：

全球病毒載體和質粒 DNA 製造市場根據載體類型、工作流程、應用、最終用途、治療領域和地區進行細分。

根據載體類型，病毒載體和質粒DNA製造市場分為腺病毒、慢病毒、腺相關病毒（AAV）、逆轉錄病毒、質粒、桿狀病毒、仙台病毒和其他（單純皰疹病毒（HSV）等） 。腺相關病毒（AAV）領域預計將在預測期內佔據最大的市場佔有率。由於 AAV 在將基因遞送到所需位置方面具有極高的精確度，因此備受歡迎，並快速用於臨床試驗。關於骨科和眼科基因治療藥物開發的臨床研究顯示療效和效率提高，這是越來越多採用的原因。

根據工作流程，病毒載體和質粒 DNA 製造業分為上游製造和下游製造。由於用於拋光和純化治療級最終產品的極其複雜的過程，預計下游製造部門將在預計期間佔據重要的市場佔有率。

根據應用，市場分為反義和 RNAi 治療、疫苗學、基因治療、組織工程、細胞治療、研究應用和其他（生物感測器等）。

根據最終用途，該行業分為製藥和生物製藥公司、合約製造組織（CMO、研究機構和其他（政府機構等））。

根據治療領域，病毒載體和質粒 DNA 製造市場分為神經疾病、感覺疾病、肌肉骨骼疾病、代謝疾病、腫瘤疾病、罕見疾病、血液疾病、免疫疾病和其他（生殖健康等）。預計腫瘤疾病領域將在預測期內佔據顯著的市場佔有率。該細分市場的成長歸因於全球癌症盛行率的上升。例如，根據國際癌症研究機構（IARC）的最新估計，預計2022年將新增 2,000 萬癌症病例，並有 970 萬人死於該疾病。五分之一的人會在一生中的某個階段罹患癌症；九分之一的男性和十二分之一的女性將死於這種疾病。因此，上述統計資料推動了細分市場的擴張。

病毒載體和質粒 DNA 製造市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。預計北美將在預測期內佔據最大的市場佔有率。這是因為該領域的合約開發組織數量不斷增加，以及企業擴大參與基因和細胞治療研究和產品開發。此外，區域公司該地區發展其生產工廠。由於有重要的市場參與者，例如提供 GMP 製造服務的 CDMO，以及使用高度創造性的製造方法進行生產，美國在北美病毒載體和質粒 DNA 製造市場中佔有最大的收入佔有率。

病毒載體與質粒 DNA 製造市場-競爭格局：

幾家主要企業實施一些策略性努力，以提高其市場地位並為客戶提供廣泛的服務。為了提高市場佔有率和收入並獲得競爭優勢，組織經常參與合作夥伴關係和協議、合資企業、擴張、服務推出、產品創新和其他推動市場成長的策略。近年來，質粒 DNA 和病毒載體市場出現了顯著的創新。質粒 DNA 和病毒載體的生產商不斷尋找新的有效解決方案，以滿足對增強基因療法和疫苗開發不斷成長的需求。使用瞬時轉染技術大規模生產病毒載體是該市場的主要發展之一。利用懸浮細胞培養技術生產病毒載體是另一種創新方法。大型生物技術和製藥公司更頻繁地收購小型載體和質粒 DNA 生產商，以獲得其專利技術、知識和製造能力。結果，出現了市場整合，增加了老牌企業在定價和市場佔有率方面的權力。透過利用大型收購方的基礎設施和資源，小型企業可以擴大業務並進入新市場。例如，2022年2月，Exelead被Merck KGaA以約7.8億美元收購。沿著 mRNA 價值鏈為最終用戶提供完整的端對端 CDMO 服務將進一步改善Merck的生命科學產品。

最近的發展：

2023年 10月，AGC Biologics 宣布擴建其德國 pDNA 製造廠。預計這將有助於企業縮短製造交貨時間。

目錄

第1章 病毒載體和質粒 DNA 製造市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 按載體類型分類的病毒載體和質粒 DNA 製造市場摘要
    • 按工作流程分類的病毒載體和質粒 DNA 製造市場摘要
    • 依應用分類的病毒載體和質粒 DNA 製造市場摘要
    • 依最終用途分類的病毒載體和質粒 DNA 製造市場摘要
    • 依治療領域分類的病毒載體和質粒 DNA 製造市場摘要
    • 依國家分類的病毒載體和質粒 DNA 製造市場摘要
    • 依地區分類的病毒載體和質粒 DNA 製造市場摘要
  • 競爭洞察

第3章 病毒載體和質粒 DNA 製造主要市場趨勢

  • 病毒載體和質粒 DNA 製造市場促進因素
    • 市場促進因素的影響分析
  • 病毒載體和質粒 DNA 製造市場限制
    • 市場限制影響分析
  • 病毒載體和質粒 DNA 製造市場機會
  • 病毒載體與質粒 DNA 製造市場未來趨勢

第4章 病毒載體與質粒 DNA 製造業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 病毒載體與質粒 DNA 製造市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 病毒載體與質粒 DNA 製造市場格局

  • 2023年病毒載體和質粒 DNA 製造市場佔有率分析
  • 按主要製造商分類的故障資料
    • 既有參與者分析
    • 新興參與者分析

第7章 病毒載體和質粒 DNA 製造市場 - 按載體類型

  • 概述
    • 按載體類型分類的細分市場佔有率分析
    • 腺病毒
    • 慢病毒
    • 腺相關病毒（AAV）
    • 逆轉錄病毒
    • 質粒
    • 桿狀病毒
    • 仙台病毒
    • 其他（單純皰疹病毒（HSV）等）

第8章 病毒載體和質粒 DNA 製造市場 - 按工作流程

  • 概述
    • 按工作流程分類的細分市場佔有率分析
    • 上游製造
      • 載體放大和擴展
      • 載體恢復/收穫
    • 下游製造
      • 純化
      • 填充完成

第9章 病毒載體和質粒 DNA 製造市場 - 依應用

  • 概述
    • 依應用分類的細分市場佔有率分析
    • 反義和 RNAi 治療
    • 疫苗學
    • 基因治療
    • 組織工程
    • 細胞療法
    • 研究應用
    • 其他（生物感測器等）

第10章 病毒載體和質粒 DNA 製造市場 - 依最終用途

  • 概述
    • 依最終用途分類的細分市場佔有率分析
    • 製藥和生物製藥公司
    • 合約製造組織（CMO）
    • 研究機構
    • 其他（政府機構等）

第11章 病毒載體和質粒 DNA 製造市場 - 依治療領域

  • 概述
    • 依治療領域分類的細分市場佔有率分析
    • 神經系統疾病
    • 感覺障礙
    • 肌肉骨骼疾病
    • 代謝紊亂
    • 腫瘤疾病
    • 罕見疾病
    • 血液疾病
    • 免疫系統疾病
    • 其他（生殖健康等）

第12章 病毒載體和質粒 DNA 製造市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美病毒載體和質粒 DNA 製造主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（按載體類型）
    • 北美市場規模和預測（按工作流程）
    • 北美市場規模和預測（依應用）
    • 北美市場規模和預測（依最終用途）
    • 北美市場規模與預測（依治療領域）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲病毒載體和質粒 DNA 製造主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（按載體類型）
    • 歐洲市場規模和預測（按工作流程）
    • 歐洲市場規模和預測（依應用）
    • 歐洲市場規模和預測（依最終用途）
    • 歐洲市場規模與預測（依治療領域）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區病毒載體和質粒 DNA 製造主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模與預測（按載體類型）
    • 亞太地區市場規模和預測（按工作流程）
    • 亞太地區市場規模與預測（依應用）
    • 亞太地區市場規模和預測（依最終用途）
    • 依治療領域分類的亞太市場規模和預測
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲病毒載體和質粒 DNA 製造主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（按載體類型）
    • 拉丁美洲市場規模和預測（按工作流程）
    • 拉丁美洲市場規模與預測（依應用）
    • 拉丁美洲市場規模和預測（依最終用途）
    • 拉丁美洲市場規模與預測（依治療領域）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲病毒載體和質粒 DNA 製造主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（按載體類型）
    • 中東和非洲市場規模及預測（按工作流程）
    • 中東和非洲市場規模及預測（依應用）
    • 中東和非洲市場規模和預測（依最終用途）
    • 中東和非洲市場規模及預測（依治療領域）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA的其他地區

第13章 主要供應商分析 - 病毒載體和質粒 DNA 製造業

  • 競爭儀表板
  • 公司簡介
    • CEVEC Pharmaceuticals
    • Catalent Biologics
    • Cobra Biologics
    • Altruist Biotechnology
    • NorthX Biologics
    • Novartis
    • BioReliance（a subsidiary of Merck KGaA）
    • Centre for Process Innovation
    • Wuxi AppTech
    • Charles River Laboratories
    • CoJourney
    • Esco Aster
    • Jiangsu Puxin Biopharmaceutical
    • Lonza
    • Advanced BioScience Laboratories
    • AGC Biologics
    • Aldevron
    • Biovian
    • Celonic
    • BioNTech Innovative Manufacturing Service（a subsidiary of BioNTech）
    • Oxford BioMedica
    • Sanofi
    • Thermo Fisher Scientific
    • VectorBuilder
    • Matica Biotechnology
    • Resilience
    • Nikon CeLL innovation

第14章 360 度分析師視角

第15章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV2473

REPORT HIGHLIGHT

Viral Vector and Plasmid DNA Manufacturing Market size was valued at USD 5,405 Million in 2023, expanding at a CAGR of 19.7% from 2024 to 2032.

Viral vectors and plasmid DNA can be employed in gene therapy to treat a wide range of diseases, such as cancer, metabolic issues, cardiac problems, and neurological disorders. As viral vectors are based on baculovirus, herpes simplex viruses, adenoviruses, and other viruses, they are being employed increasingly frequently in vaccine research and the development of novel medications.

Viral Vector and Plasmid DNA Manufacturing Market- Market Dynamics

Increasing government support for cell-based research to propel market demand

The market for Viral Vector and Plasmid DNA Manufacturing is expected to grow as a result of increased government funding for the creation of new technologies and facilities for producing viral vectors, which has increased overall research activity and supported cell-based research. In addition, the main drivers propelling market expansion are the growing prevalence of diseases including cancer and heart abnormalities, the use of cell therapies research, and technological advancements in the field of viral vector & plasmid DNA manufacture. For instance, the Canadian government made investments in genomics and regenerative medicine to promote the health of its citizens. Through the competitive research funding initiative of the Stem Cell Network, $4.3 million was awarded. 16 initiatives from around Canada that aim to treat health issues like multiple sclerosis, muscular dystrophy, cancer, blood diseases, diabetes type 1, heart disease, and cystic fibrosis will be supported by this direct funding. A new program to assist early career researchers in the health, bioengineering, and social sciences who are creating stem cell research initiatives with an emphasis on regenerative medicine was one of the funding opportunities featured in this competition. In addition, $16 million will be provided to ten new genomics studies through Genome Canada. By 2035, this investment will have contributed to the transformation of biomedicine and drug development. It will also support mission-driven research with direct application potential that tackles real-world problems and possibilities in the fields of agriculture, health, and the environment.

Rising product launches offer a potential opportunity for market revenue growth

The increasing product launch is expected to offer a potential opportunity for market growth during the forecast period. For instance, in March 2023, Adeno-associated virus (AAV)-based gene therapy initiatives can now be more efficiently managed from early discovery to commercial manufacture with the introduction of Charles River Laboratories International, Inc.'s off-the-shelf pHelper service. Research Grade (RG), High Quality (HQ), and Good Manufacturing Practice (GMP) grades are all instantly available.

Viral Vector and Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.7% over the forecast period (2024-2032)

Based on vector type segmentation, the Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period

Based on workflow segmentation, the Downstream Manufacturing segment is expected to hold a significant market share over the projected period

Based on the therapeutic area, the oncological disorder segment is expected to hold a prominent market share over the forecast period

Based on region, North America was the leading revenue generator in 2023

Viral Vector and Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented based on Vector Type, Workflow, Application, End-use, Therapeutic Area, and Region.

Based on the vector type, the Viral Vector and Plasmid DNA Manufacturing market is segmented into Adenovirus, Lentivirus, Adeno-Associated Virus (AAV), Retrovirus, Plasmids, Baculovirus, Sendai Virus and Others (Herpes Simplex Virus (HSV), etc.). The Adeno-Associated Virus (AAV) segment is expected to hold the largest market share over the forecast period. Due to their exceptional precision in delivering the gene to the desired location, AAVs are extremely sought after and are being used in clinical trials at a rapid pace. Clinical investigations about the development of orthopedic and ophthalmic gene therapy medicines are showing enhanced efficacy and efficiency, which is the reason for the increasing adoption.

Based on the workflow, the Viral Vector and Plasmid DNA Manufacturing industry is bifurcated into Upstream Manufacturing and Downstream Manufacturing. The Downstream Manufacturing segment is expected to hold a significant market share over the projected period due to the extremely intricate processes used to polish and purify final products of therapeutic grade.

Based on the application, the market is bifurcated into Antisense & RNAi Therapy, Vaccinology, Gene Therapy, Tissue Engineering, Cell Therapy, Research Applications and Others (Biosensors, etc.).

Based on the end-use, the industry is bifurcated into Pharmaceutical and Biopharmaceutical Companies, Contract Manufacturing Organizations (CMOs, Research Institutes and Others (Government Agencies, etc.).

Based on the therapeutic area, the Viral Vector and Plasmid DNA Manufacturing market is bifurcated into Neurological Disorders, Sensory Disorders, Musculoskeletal Disorders, Metabolic Disorders, Oncological Disorders, Rare Diseases, Blood Disorders, Immunological Disorders and Others (Reproductive Health, etc.). The oncological disorder segment is expected to hold a prominent market share over the forecast period. The segment growth is attributed to the rising prevalence of cancer across the globe. For instance, according to the latest estimates by the International Agency for Research on Cancer (IARC), 20 million new instances of cancer and 9.7 million deaths from the disease are anticipated for 2022. 53.5 million people were predicted to still be alive five years after receiving a cancer diagnosis. One in five people will have cancer at some point in their lives; one in nine men and one in twelve women will pass away from the disease. Thus, the aforementioned statistics propel the segment expansion.

Viral Vector and Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to hold the largest market share over the forecast period. This is explained by the increasing number of contract development organizations in the area as well as the increasing involvement of businesses in gene and cell therapy research and product development. Furthermore, regional companies are growing their production plants in the area. Due to the existence of significant market participants, such as CDMOs providing GMP manufacturing services, and the use of highly creative manufacturing methods for production, the United States held the largest revenue share in the North American market for viral vectors and plasmid DNA manufacturing.

Viral Vector and Plasmid DNA Manufacturing Market- Competitive Landscape:

Several major businesses are implementing some strategic efforts to improve their market position and provide a wide range of services to customers. To boost market presence and revenue and obtain a competitive edge, organizations frequently engage in partnerships and agreements, joint ventures, expansion, service launches, product innovation and other tactics that fuel market growth. Recent years have seen a notable level of innovation in the market for plasmid DNA and viral vectors. Producers of plasmid DNA and viral vectors are continuously looking for new and effective solutions to meet the growing demand for enhanced gene therapy and vaccine development. The use of transient transfection technology for the large-scale manufacturing of viral vectors is one of the major developments in this market. Utilizing suspension cell culture techniques to produce viral vectors is another innovative approach. Big biotech and pharmaceutical corporations are buying up smaller vector and plasmid DNA producers more frequently to gain access to their patented technologies, knowledge, and manufacturing capabilities. As a result, there is market consolidation, which increases the power of established players over pricing and market share. By utilizing the infrastructure and resources of larger acquirers, smaller businesses can expand their operations and reach new markets. For instance, in February 2022, Exelead was purchased by Merck KGaA for around USD 780 million. Providing end users with full end-to-end CDMO services along the mRNA value chain would further improve Merck's Life Science offering.

Recent Developments:

In October 2023, AGC Biologics announced the expansion of their German pDNA manufacturing facility. It is anticipated that this will assist the business in shortening the manufacturing lead time.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

CEVEC Pharmaceuticals

Catalent Biologics

Cobra Biologics

Altruist Biotechnology

NorthX Biologics

Novartis

BioReliance (a subsidiary of Merck KGaA)

Centre for Process Innovation

Wuxi AppTech

Charles River Laboratories

CoJourney

Esco Aster

Jiangsu Puxin Biopharmaceutical

Lonza

Advanced BioScience Laboratories

AGC Biologics

Aldevron

Biovian

Celonic

BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)

Oxford BioMedica

Sanofi

Thermo Fisher Scientific

VectorBuilder

Matica Biotechnology

Resilience

Nikon CeLL innovation

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY VECTOR TYPE- MARKET ANALYSIS, 2019 - 2032

  • Adenovirus
  • Lentivirus
  • Adeno-Associated Virus (AAV)
  • Retrovirus
  • Plasmids
  • Baculovirus
  • Sendai Virus
  • Others (Herpes Simplex Virus (HSV), etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW- MARKET ANALYSIS, 2019 - 2032

  • Upstream Manufacturing
  • Vector Amplification & Expansion
  • Vector Recovery/Harvesting
  • Downstream Manufacturing
  • Purification
  • Fill Finish

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Antisense & RNAi Therapy
  • Vaccinology
  • Gene Therapy
  • Tissue Engineering
  • Cell Therapy
  • Research Applications
  • Others (Biosensors, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical and Biopharmaceutical Companies
  • Contract Manufacturing Organizations (CMOs)
  • Research Institutes
  • Others (Government Agencies, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Neurological Disorders
  • Sensory Disorders
  • Musculoskeletal Disorders
  • Metabolic Disorders
  • Oncological Disorders
  • Rare Diseases
  • Blood Disorders
  • Immunological Disorders
  • Others (Reproductive Health, etc.)

GLOBAL VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Viral Vector and Plasmid DNA Manufacturing Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Vector Type
    • 2.1.2. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Workflow
    • 2.1.3. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Application
    • 2.1.4. Viral Vector and Plasmid DNA Manufacturing Market Snippet by End-use
    • 2.1.5. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Therapeutic Area
    • 2.1.6. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Country
    • 2.1.7. Viral Vector and Plasmid DNA Manufacturing Market Snippet by Region
  • 2.2. Competitive Insights

3. Viral Vector and Plasmid DNA Manufacturing Key Market Trends

  • 3.1. Viral Vector and Plasmid DNA Manufacturing Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Viral Vector and Plasmid DNA Manufacturing Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Viral Vector and Plasmid DNA Manufacturing Market Opportunities
  • 3.4. Viral Vector and Plasmid DNA Manufacturing Market Future Trends

4. Viral Vector and Plasmid DNA Manufacturing Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Viral Vector and Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Viral Vector and Plasmid DNA Manufacturing Market Landscape

  • 6.1. Viral Vector and Plasmid DNA Manufacturing Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Viral Vector and Plasmid DNA Manufacturing Market - By Vector Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Vector Type, 2023 & 2032 (%)
    • 7.1.2. Adenovirus
    • 7.1.3. Lentivirus
    • 7.1.4. Adeno-Associated Virus (AAV)
    • 7.1.5. Retrovirus
    • 7.1.6. Plasmids
    • 7.1.7. Baculovirus
    • 7.1.8. Sendai Virus
    • 7.1.9. Others (Herpes Simplex Virus (HSV), etc.)

8. Viral Vector and Plasmid DNA Manufacturing Market - By Workflow

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Workflow, 2023 & 2032 (%)
    • 8.1.2. Upstream Manufacturing
      • 8.1.2.1. Vector Amplification & Expansion
      • 8.1.2.2. Vector Recovery/Harvesting
    • 8.1.3. Downstream Manufacturing
      • 8.1.3.1. Purification
      • 8.1.3.2. Fill Finish

9. Viral Vector and Plasmid DNA Manufacturing Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 9.1.2. Antisense & RNAi Therapy
    • 9.1.3. Vaccinology
    • 9.1.4. Gene Therapy
    • 9.1.5. Tissue Engineering
    • 9.1.6. Cell Therapy
    • 9.1.7. Research Applications
    • 9.1.8. Others (Biosensors, etc.)

10. Viral Vector and Plasmid DNA Manufacturing Market - By End-use

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-use, 2023 & 2032 (%)
    • 10.1.2. Pharmaceutical and Biopharmaceutical Companies
    • 10.1.3. Contract Manufacturing Organizations (CMOs)
    • 10.1.4. Research Institutes
    • 10.1.5. Others (Government Agencies, etc.)

11. Viral Vector and Plasmid DNA Manufacturing Market - By Therapeutic Area

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Therapeutic Area, 2023 & 2032 (%)
    • 11.1.2. Neurological Disorders
    • 11.1.3. Sensory Disorders
    • 11.1.4. Musculoskeletal Disorders
    • 11.1.5. Metabolic Disorders
    • 11.1.6. Oncological Disorders
    • 11.1.7. Rare Diseases
    • 11.1.8. Blood Disorders
    • 11.1.9. Immunological Disorders
    • 11.1.10. Others (Reproductive Health, etc.)

12. Viral Vector and Plasmid DNA Manufacturing Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Viral Vector and Plasmid DNA Manufacturing Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Vector Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Workflow, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End-use, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Viral Vector and Plasmid DNA Manufacturing Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. CEVEC Pharmaceuticals
    • 13.2.2. Catalent Biologics
    • 13.2.3. Cobra Biologics
    • 13.2.4. Altruist Biotechnology
    • 13.2.5. NorthX Biologics
    • 13.2.6. Novartis
    • 13.2.7. BioReliance (a subsidiary of Merck KGaA)
    • 13.2.8. Centre for Process Innovation
    • 13.2.9. Wuxi AppTech
    • 13.2.10. Charles River Laboratories
    • 13.2.11. CoJourney
    • 13.2.12. Esco Aster
    • 13.2.13. Jiangsu Puxin Biopharmaceutical
    • 13.2.14. Lonza
    • 13.2.15. Advanced BioScience Laboratories
    • 13.2.16. AGC Biologics
    • 13.2.17. Aldevron
    • 13.2.18. Biovian
    • 13.2.19. Celonic
    • 13.2.20. BioNTech Innovative Manufacturing Service (a subsidiary of BioNTech)
    • 13.2.21. Oxford BioMedica
    • 13.2.22. Sanofi
    • 13.2.23. Thermo Fisher Scientific
    • 13.2.24. VectorBuilder
    • 13.2.25. Matica Biotechnology
    • 13.2.26. Resilience
    • 13.2.27. Nikon CeLL innovation

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Vector Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Vector Type
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Workflow Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Workflow
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Workflow 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Application Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Application
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Application 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: End-use Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-use
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by End-use 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Therapeutic Area Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Therapeutic Area
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area 2019-2032 (USD Million)
  • TABLE Viral Vector and Plasmid DNA Manufacturing Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Viral Vector and Plasmid DNA Manufacturing Market, by Region 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE North America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Europe Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Latin America Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Vector Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Workflow, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by End-use, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Viral Vector and Plasmid DNA Manufacturing Market, by Therapeutic Area, 2019-2032 (USD Million)